Spironolactone Benefits Exercise Tolerance in HFpEF

Share this content:
Spironolactone Benefits Exercise Tolerance in HFpEF
Spironolactone Benefits Exercise Tolerance in HFpEF

TUESDAY, Oct. 18, 2016 (HealthDay News) -- For patients with heart failure with preserved ejection fraction (HFpEF) with an exercise-induced increase in the ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e'), spironolactone is associated with improved exercise capacity, according to a study published in the Oct. 25 issue of the Journal of the American College of Cardiology.

Wojciech Kosmala, M.D., Ph.D., from the Wroclaw Medical University in Poland, and colleagues conducted a randomized, placebo-controlled trial involving 150 subjects with exertional dyspnea. Patients were randomly allocated to six months of oral spironolactone or matching placebo. A total of 131 patients had completed therapy at follow-up (64 taking spironolactone and 67 taking placebo).

The researchers found that subjects had substantial exercise limitation at baseline. Improvements were seen in exercise capacity (P < 0.001), anaerobic threshold (P = 0.03), and oxygen uptake efficiency (P = 0.002) in the spironolactone group, with a reduction in E/e' (P < 0.001). A significant interaction was seen for spironolactone and the change in E/e' on peak oxygen uptake (P = 0.039).

"In patients with HFpEF and abnormal diastolic response to exertion, improvement in exercise E/e' mediates the beneficial effect of spironolactone on exercise capacity," the authors write. "Identification of exercise-induced increase in left ventricular filling pressure in patients with HFpEF may define a subgroup with warranting trial of spironolactone."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »